Ferrlecit Generic To Get 3-Part Evaluation After FDA Worry On Therapeutic Equivalence
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis’ version of Sanofi’s brand comes under scrutiny after EU guidance suggests generic iron formulations could have higher levels of labile iron and that study of plasma levels alone “may conceivably fail to detect relevant differences in the tissue distribution of iron.”
You may also be interested in...
Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
Watson's own citizen petitions blocking generics won't be an obstacle, company says.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.